BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28:1145-1153. [PMID: 20100965 DOI: 10.1200/jco.2009.22.4725] [Cited by in Crossref: 642] [Cited by in F6Publishing: 333] [Article Influence: 58.4] [Reference Citation Analysis]
Number Citing Articles
1 Agnello L, Tortorella S, d'Argenio A, Carbone C, Camorani S, Locatelli E, Auletta L, Sorrentino D, Fedele M, Zannetti A, Franchini MC, Cerchia L. Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors. J Exp Clin Cancer Res 2021;40:239. [PMID: 34294133 DOI: 10.1186/s13046-021-02039-w] [Reference Citation Analysis]
2 Heyn H, Carmona FJ, Gomez A, Ferreira HJ, Bell JT, Sayols S, Ward K, Stefansson OA, Moran S, Sandoval J, Eyfjord JE, Spector TD, Esteller M. DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker. Carcinogenesis 2013;34:102-8. [PMID: 23054610 DOI: 10.1093/carcin/bgs321] [Cited by in Crossref: 106] [Cited by in F6Publishing: 78] [Article Influence: 11.8] [Reference Citation Analysis]
3 Girgert R, Emons G, Gründker C. Inhibition of growth hormone receptor by Somavert reduces expression of GPER and prevents growth stimulation of triple-negative breast cancer by 17β-estradiol. Oncol Lett 2018;15:9559-66. [PMID: 29805678 DOI: 10.3892/ol.2018.8521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
4 Donovan MG, Selmin OI, Doetschman TC, Romagnolo DF. Epigenetic Activation of BRCA1 by Genistein In Vivo and Triple Negative Breast Cancer Cells Linked to Antagonism toward Aryl Hydrocarbon Receptor. Nutrients 2019;11:E2559. [PMID: 31652854 DOI: 10.3390/nu11112559] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
5 Gucalp A, Traina TA. Triple-negative breast cancer: adjuvant therapeutic options. Chemother Res Pract 2011;2011:696208. [PMID: 22312556 DOI: 10.1155/2011/696208] [Cited by in Crossref: 18] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
6 Giacchetti S, Porcher R, Lehmann-Che J, Hamy AS, de Roquancourt A, Cuvier C, Cottu PH, Bertheau P, Albiter M, Bouhidel F, Coussy F, Extra JM, Marty M, de Thé H, Espié M. Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen. Br J Cancer 2014;110:1413-9. [PMID: 24569467 DOI: 10.1038/bjc.2014.81] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
7 Maennling AE, Tur MK, Niebert M, Klockenbring T, Zeppernick F, Gattenlöhner S, Meinhold-Heerlein I, Hussain AF. Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials. Cancers (Basel) 2019;11:E1826. [PMID: 31756933 DOI: 10.3390/cancers11121826] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 23.0] [Reference Citation Analysis]
8 Amos KD, Adamo B, Anders CK. Triple-negative breast cancer: an update on neoadjuvant clinical trials. Int J Breast Cancer 2012;2012:385978. [PMID: 22461984 DOI: 10.1155/2012/385978] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
9 Kim JE, Ahn HJ, Ahn JH, Yoon DH, Kim SB, Jung KH, Gong GY, Kim MJ, Son BH, Ahn SH. Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer. J Breast Cancer 2012;15:197-202. [PMID: 22807937 DOI: 10.4048/jbc.2012.15.2.197] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
10 Dieci MV, Del Mastro L, Cinquini M, Montemurro F, Biganzoli L, Cortesi L, Zambelli A, Criscitiello C, Levaggi A, Conte B, Calabrese M, Fiorentino A, Marchiò C, Tinterri C, Fittipaldo VA, Pappagallo G, Gori S. Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM). Cancers (Basel) 2019;11:E1137. [PMID: 31398896 DOI: 10.3390/cancers11081137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Hicks C, Kumar R, Pannuti A, Backus K, Brown A, Monico J, Miele L. An Integrative Genomics Approach for Associating GWAS Information with Triple-Negative Breast Cancer. Cancer Inform 2013;12:1-20. [PMID: 23423317 DOI: 10.4137/CIN.S10413] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
12 Su YW, Hung CY, Lam HB, Chang YC, Yang PS. A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status. Clin Med Insights Oncol 2018;12:1179554918794672. [PMID: 30150877 DOI: 10.1177/1179554918794672] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
13 Garmpis N, Damaskos C, Garmpi A, Nikolettos K, Dimitroulis D, Diamantis E, Farmaki P, Patsouras A, Voutyritsa E, Syllaios A, Zografos CG, Antoniou EA, Nikolettos N, Kostakis A, Kontzoglou K, Schizas D, Nonni A. Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast Cancer. In Vivo 2020;34:1715-27. [PMID: 32606140 DOI: 10.21873/invivo.11965] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
14 Sardesai S, Badawi M, Mrozek E, Morgan E, Phelps M, Stephens J, Wei L, Kassem M, Ling Y, Lustberg M, Stover D, Williams N, Layman R, Reinbolt R, VanDeusen J, Cherian M, Grever M, Carson W, Ramaswamy B, Wesolowski R. A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer. Invest New Drugs 2020;38:1400-10. [PMID: 31953695 DOI: 10.1007/s10637-020-00895-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
15 Papadimitriou K, Ardavanis A, Kountourakis P. Neoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium. J Thorac Dis 2010;2:160-70. [PMID: 22263038 DOI: 10.3978/j.issn.2072-1439.2010.02.03.8] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
16 Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125:627-636. [PMID: 21161370 DOI: 10.1007/s10549-010-1293-1] [Cited by in Crossref: 194] [Cited by in F6Publishing: 180] [Article Influence: 17.6] [Reference Citation Analysis]
17 O'Brien K, Lowry MC, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RA, O'Driscoll L. miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget 2015;6:32774-89. [PMID: 26416415 DOI: 10.18632/oncotarget.5192] [Cited by in Crossref: 123] [Cited by in F6Publishing: 123] [Article Influence: 24.6] [Reference Citation Analysis]
18 Dębska-Szmich S, Krakowska M, Czernek U, Habib-Lisik M, Zięba A, Potemski P. The role of preoperative systemic treatment in patients with breast cancer. Contemp Oncol (Pozn) 2016;20:93-101. [PMID: 27358586 DOI: 10.5114/wo.2016.60067] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Imyanitov EN, Byrski T. Systemic treatment for hereditary cancers: a 2012 update. Hered Cancer Clin Pract 2013;11:2. [PMID: 23548133 DOI: 10.1186/1897-4287-11-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
20 Alli E, Sharma VB, Hartman AR, Lin PS, McPherson L, Ford JM. Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol 2011;11:7. [PMID: 21771338 DOI: 10.1186/1471-2210-11-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
21 Li Q, Li Q, Zhang P, Yuan P, Wang J, Ma F, Luo Y, Fan Y, Cai R, Xu B. A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes. Cancer Biol Ther 2015;16:1746-53. [PMID: 26466918 DOI: 10.1080/15384047.2015.1095400] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
22 Shao Z, Chaudhri S, Guo M, Zhang L, Rea D. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study. Oncol Res 2016;23:291-302. [PMID: 27131315 DOI: 10.3727/096504016X14562725373879] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
23 Lehmann BD, Pietenpol JA. Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast 2015;24 Suppl 2:S36-40. [PMID: 26253813 DOI: 10.1016/j.breast.2015.07.009] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 10.3] [Reference Citation Analysis]
24 Palvai S, Anandi L, Sarkar S, Augustus M, Roy S, Lahiri M, Basu S. Drug-Triggered Self-Assembly of Linear Polymer into Nanoparticles for Simultaneous Delivery of Hydrophobic and Hydrophilic Drugs in Breast Cancer Cells. ACS Omega 2017;2:8730-40. [PMID: 30023590 DOI: 10.1021/acsomega.7b01400] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Lips EH, Michaut M, Hoogstraat M, Mulder L, Besselink NJ, Koudijs MJ, Cuppen E, Voest EE, Bernards R, Nederlof PM, Wesseling J, Rodenhuis S, Wessels LF; Center for Personalized Cancer Treatment. Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response. Breast Cancer Res 2015;17:134. [PMID: 26433948 DOI: 10.1186/s13058-015-0642-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
26 Li Y, Huang S, Wei Z, Yang B. A putative competing endogenous RNA network in cisplatin-resistant lung adenocarcinoma cells identifying potentially rewarding research targets. Oncol Lett 2020;19:4040-52. [PMID: 32382346 DOI: 10.3892/ol.2020.11483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Pal T, Vadaparampil ST. Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting. Cancer Control 2012;19:255-66. [PMID: 23037493 DOI: 10.1177/107327481201900402] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
28 Liu J, Ding H, Quan H, Han J. Anthelminthic niclosamide inhibits tumor growth and invasion in cisplatin-resistant human epidermal growth factor receptor 2-positive breast cancer. Oncol Lett 2021;22:666. [PMID: 34386088 DOI: 10.3892/ol.2021.12927] [Reference Citation Analysis]
29 Shin VY, Siu JM, Cheuk I, Ng EK, Kwong A. Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. Br J Cancer. 2015;112:1751-1759. [PMID: 25906045 DOI: 10.1038/bjc.2015.143] [Cited by in Crossref: 87] [Cited by in F6Publishing: 78] [Article Influence: 14.5] [Reference Citation Analysis]
30 Anders CK, Zagar TM, Carey LA. The management of early-stage and metastatic triple-negative breast cancer: a review. Hematol Oncol Clin North Am 2013;27:737-49, viii. [PMID: 23915742 DOI: 10.1016/j.hoc.2013.05.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
31 Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y. Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers. Cancer Sci 2018;109:166-73. [PMID: 29047188 DOI: 10.1111/cas.13426] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
32 Hill SJ, Clark AP, Silver DP, Livingston DM. BRCA1 pathway function in basal-like breast cancer cells. Mol Cell Biol 2014;34:3828-42. [PMID: 25092866 DOI: 10.1128/MCB.01646-13] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
33 Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, Richardson AL, Wang ZC. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 2010;16:214-8. [PMID: 20098429 DOI: 10.1038/nm.2090] [Cited by in Crossref: 216] [Cited by in F6Publishing: 191] [Article Influence: 19.6] [Reference Citation Analysis]
34 Wang J, Zhang H, Yin X, Bian Y. Anti-CD47 antibody synergizes with cisplatin against laryngeal cancer by enhancing phagocytic ability of macrophages. Clin Exp Immunol 2021;205:333-42. [PMID: 33999416 DOI: 10.1111/cei.13618] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2012;2:366-75. [PMID: 22576213 DOI: 10.1158/2159-8290.CD-11-0206] [Cited by in Crossref: 250] [Cited by in F6Publishing: 129] [Article Influence: 27.8] [Reference Citation Analysis]
36 Campos-Parra AD, Mitznahuatl GC, Pedroza-Torres A, Romo RV, Reyes FIP, López-Urrutia E, Pérez-Plasencia C. Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications. Int J Mol Sci 2017;18:E1182. [PMID: 28574440 DOI: 10.3390/ijms18061182] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
37 Garutti M, Pelizzari G, Bartoletti M, Malfatti MC, Gerratana L, Tell G, Puglisi F. Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors. Int J Mol Sci. 2019;20. [PMID: 31295913 DOI: 10.3390/ijms20143390] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
38 Gunebakan E, Yalcin E, Dulger EC, Yigitbasi A, Ates N, Caglayan A, Beker MC, Sahin K, Korkaya H, Kilic E. Short-Term Diet Restriction but Not Alternate Day Fasting Prevents Cisplatin-Induced Nephrotoxicity in Mice. Biomedicines 2020;8:E23. [PMID: 32028692 DOI: 10.3390/biomedicines8020023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
39 Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med. 2012;12:96-110. [PMID: 22082486 DOI: 10.2174/156652412798376134] [Cited by in Crossref: 120] [Cited by in F6Publishing: 98] [Article Influence: 13.3] [Reference Citation Analysis]
40 Kamalakaran S, Varadan V, Janevski A, Banerjee N, Tuck D, McCombie WR, Dimitrova N, Harris LN. Translating next generation sequencing to practice: opportunities and necessary steps. Mol Oncol 2013;7:743-55. [PMID: 23769412 DOI: 10.1016/j.molonc.2013.04.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
41 Davis SL, Eckhardt SG, Tentler JJ, Diamond JR. Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers. Ther Adv Med Oncol 2014;6:88-100. [PMID: 24790649 DOI: 10.1177/1758834013519843] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
42 Baek DW, Park JY, Lee SJ, Chae YS. Impressive effect of cisplatin monotherapy on a patient with heavily pretreated triple-negative breast cancer with poor performance. Yeungnam Univ J Med 2020;37:230-5. [PMID: 31962039 DOI: 10.12701/yujm.2019.00423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Pern F, Bogdanova N, Schürmann P, Lin M, Ay A, Länger F, Hillemanns P, Christiansen H, Park-Simon TW, Dörk T. Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer. PLoS One 2012;7:e47993. [PMID: 23110154 DOI: 10.1371/journal.pone.0047993] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
44 Wu K, Yang Q, Liu Y, Wu A, Yang Z. Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy. World J Surg Oncol 2014;12:95. [PMID: 24731479 DOI: 10.1186/1477-7819-12-95] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
45 Donovan MG, Wren SN, Cenker M, Selmin OI, Romagnolo DF. Dietary fat and obesity as modulators of breast cancer risk: Focus on DNA methylation. Br J Pharmacol 2020;177:1331-50. [PMID: 31691272 DOI: 10.1111/bph.14891] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
46 Ricci AD, Rizzo A, Bonucci C, Tober N, Palloni A, Mollica V, Maggio I, Deserti M, Tavolari S, Brandi G. PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block? Medicines (Basel) 2020;7:E54. [PMID: 32878011 DOI: 10.3390/medicines7090054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
47 Yang L, Perez AA, Fujie S, Warden C, Li J, Wang Y, Yung B, Chen YR, Liu X, Zhang H, Zheng S, Liu Z, Ann D, Yen Y. Wnt modulates MCL1 to control cell survival in triple negative breast cancer. BMC Cancer 2014;14:124. [PMID: 24564888 DOI: 10.1186/1471-2407-14-124] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
48 Huang L, Liu Q, Chen S, Shao Z. Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer. Onco Targets Ther 2017;10:5739-44. [PMID: 29238206 DOI: 10.2147/OTT.S145934] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
49 Bertucci F, Finetti P, Goncalves A, Birnbaum D. The therapeutic response of ER+/HER2- breast cancers differs according to the molecular Basal or Luminal subtype. NPJ Breast Cancer 2020;6:8. [PMID: 32195331 DOI: 10.1038/s41523-020-0151-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
50 Sanders MA, Haynes B, Nangia-Makker P, Polin LA, Shekhar MP. Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs. J Biol Chem 2017;292:10347-63. [PMID: 28490629 DOI: 10.1074/jbc.M117.792192] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
51 Sikov WM. Assessing the role of platinum agents in aggressive breast cancers. Curr Oncol Rep 2015;17:3. [PMID: 25665554 DOI: 10.1007/s11912-014-0428-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
52 Yamamoto Y, Iwase H. Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol 2010;15:341-51. [PMID: 20632057 DOI: 10.1007/s10147-010-0106-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
53 Drost R, Dhillon KK, van der Gulden H, van der Heijden I, Brandsma I, Cruz C, Chondronasiou D, Castroviejo-Bermejo M, Boon U, Schut E, van der Burg E, Wientjens E, Pieterse M, Klijn C, Klarenbeek S, Loayza-Puch F, Elkon R, van Deemter L, Rottenberg S, van de Ven M, Dekkers DH, Demmers JA, van Gent DC, Agami R, Balmaña J, Serra V, Taniguchi T, Bouwman P, Jonkers J. BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. J Clin Invest 2016;126:2903-18. [PMID: 27454287 DOI: 10.1172/JCI70196] [Cited by in Crossref: 66] [Cited by in F6Publishing: 39] [Article Influence: 13.2] [Reference Citation Analysis]
54 Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Wesseling J, Vd Vijver MJ, de Vries EG, van Tinteren H, Jonkers J, Hauptmann M. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res. 2014;16:R47. [PMID: 24887359 DOI: 10.1186/bcr3655] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 8.7] [Reference Citation Analysis]
55 Li L. BRCA1 forks over new roles in DNA-damage response- before and beyond the breaks. Mol Cell 2011;44:174-6. [PMID: 22017867 DOI: 10.1016/j.molcel.2011.10.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
56 Vollebergh MA, Lips EH, Nederlof PM, Wessels LFA, Schmidt MK, van Beers EH, Cornelissen S, Holtkamp M, Froklage FE, de Vries EGE, Schrama JG, Wesseling J, van de Vijver MJ, van Tinteren H, de Bruin M, Hauptmann M, Rodenhuis S, Linn SC. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 2011;22:1561-70. [PMID: 21135055 DOI: 10.1093/annonc/mdq624] [Cited by in Crossref: 124] [Cited by in F6Publishing: 101] [Article Influence: 11.3] [Reference Citation Analysis]
57 Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pêgo A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, Melezínková H, Awada A. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013;31:2586-92. [PMID: 23733761 DOI: 10.1200/JCO.2012.46.2408] [Cited by in Crossref: 219] [Cited by in F6Publishing: 127] [Article Influence: 27.4] [Reference Citation Analysis]
58 Ademuyiwa FO, Ellis MJ, Ma CX. Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer. J Oncol 2013;2013:219869. [PMID: 23983689 DOI: 10.1155/2013/219869] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
59 Lee J, Kim HH, Ro SM, Yang JH. Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer. PLoS One 2017;12:e0171605. [PMID: 28234911 DOI: 10.1371/journal.pone.0171605] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
60 Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 2010;10:803-8. [PMID: 20944665 DOI: 10.1038/nrc2946] [Cited by in Crossref: 264] [Cited by in F6Publishing: 235] [Article Influence: 24.0] [Reference Citation Analysis]
61 Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, Elia M, Connor CS, McGinness MK, Mammen JM, Wagner JL, Ward C, Ranallo L, Knight CJ, Stecklein SR, Jensen RA, Fabian CJ, Godwin AK. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat 2014;145:707-14. [PMID: 24807107 DOI: 10.1007/s10549-014-2980-0] [Cited by in Crossref: 91] [Cited by in F6Publishing: 80] [Article Influence: 13.0] [Reference Citation Analysis]
62 Toft DJ, Cryns VL. Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol 2011;25:199-211. [PMID: 20861225 DOI: 10.1210/me.2010-0164] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 8.6] [Reference Citation Analysis]
63 Mukherjee S, Adhikary S, Gadad SS, Mondal P, Sen S, Choudhari R, Singh V, Adhikari S, Mandal P, Chaudhuri S, Sengupta A, Lakshmanaswamy R, Chakrabarti P, Roy S, Das C. Suppression of poised oncogenes by ZMYND8 promotes chemo-sensitization. Cell Death Dis 2020;11:1073. [PMID: 33323928 DOI: 10.1038/s41419-020-03129-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
64 Rubovszky G, Horváth Z. Recent Advances in the Neoadjuvant Treatment of Breast Cancer. J Breast Cancer 2017;20:119-31. [PMID: 28690648 DOI: 10.4048/jbc.2017.20.2.119] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
65 Tegze B, Szállási Z, Haltrich I, Pénzváltó Z, Tóth Z, Likó I, Gyorffy B. Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance. PLoS One 2012;7:e30804. [PMID: 22319589 DOI: 10.1371/journal.pone.0030804] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
66 Lachapelle J, Foulkes WD. Triple-negative and basal-like breast cancer: implications for oncologists. Curr Oncol 2011;18:161-4. [PMID: 21874112 DOI: 10.3747/co.v18i4.824] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
67 Wang S, Scharadin TM, Zimmermann M, Malfatti MA, Turteltaub KW, de Vere White R, Pan CX, Henderson PT. Correlation of Platinum Cytotoxicity to Drug-DNA Adduct Levels in a Breast Cancer Cell Line Panel. Chem Res Toxicol 2018;31:1293-304. [PMID: 30381944 DOI: 10.1021/acs.chemrestox.8b00170] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
68 Ratanaphan A. A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer. Int J Mol Sci 2012;13:14898-916. [PMID: 23203101 DOI: 10.3390/ijms131114898] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
69 Petrich A, Nabhan C. Use of class I histone deacetylase inhibitor romidepsin in combination regimens. Leuk Lymphoma 2016;57:1755-65. [PMID: 27118119 DOI: 10.3109/10428194.2016.1160082] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
70 Metge BJ, Mitra A, Chen D, Shevde LA, Samant RS. N-Myc and STAT Interactor regulates autophagy and chemosensitivity in breast cancer cells. Sci Rep 2015;5:11995. [PMID: 26146406 DOI: 10.1038/srep11995] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
71 Holanek M, Selingerova I, Bilek O, Kazda T, Fabian P, Foretova L, Zvarikova M, Obermannova R, Kolouskova I, Coufal O, Petrakova K, Svoboda M, Poprach A. Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence. Cancers (Basel) 2021;13:1586. [PMID: 33808149 DOI: 10.3390/cancers13071586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30:2615-2623. [PMID: 22665533 DOI: 10.1200/jco.2010.34.5579] [Cited by in Crossref: 304] [Cited by in F6Publishing: 181] [Article Influence: 33.8] [Reference Citation Analysis]
73 Yin Y, Zhang P, Xu BH, Zhang BL, Li Q, Yuan P, Cai RG, Wang JY, Wang X, Xu XZ. Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer. J Huazhong Univ Sci Technolog Med Sci 2013;33:262-5. [PMID: 23592141 DOI: 10.1007/s11596-013-1108-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
74 Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-47. [PMID: 21709140 DOI: 10.1093/annonc/mdr304] [Cited by in Crossref: 2110] [Cited by in F6Publishing: 1747] [Article Influence: 211.0] [Reference Citation Analysis]
75 Choo JR, Nielsen TO. Biomarkers for Basal-like Breast Cancer. Cancers (Basel) 2010;2:1040-65. [PMID: 24281106 DOI: 10.3390/cancers2021040] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
76 Jin J, Zhang W, Ji W, Yang F, Guan X. Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy. Cancer Biol Ther 2017;18:369-78. [PMID: 28494179 DOI: 10.1080/15384047.2017.1323582] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
77 Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget 2015;6:12890-908. [PMID: 25973541 DOI: 10.18632/oncotarget.3849] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 13.4] [Reference Citation Analysis]
78 Bouchalova K, Svoboda M, Kharaishvili G, Vrbkova J, Bouchal J, Trojanec R, Koudelakova V, Radova L, Cwiertka K, Hajduch M, Kolar Z. BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy. Tumour Biol 2015;36:4243-52. [PMID: 25616695 DOI: 10.1007/s13277-015-3061-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
79 Varela I, Klijn C, Stephens PJ, Mudie LJ, Stebbings L, Galappaththige D, van der Gulden H, Schut E, Klarenbeek S, Campbell PJ, Wessels LF, Stratton MR, Jonkers J, Futreal PA, Adams DJ. Somatic structural rearrangements in genetically engineered mouse mammary tumors. Genome Biol 2010;11:R100. [PMID: 20942901 DOI: 10.1186/gb-2010-11-10-r100] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
80 Vollebergh MA, Jonkers J, Linn SC. Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. Cell Mol Life Sci 2012;69:223-45. [PMID: 21922196 DOI: 10.1007/s00018-011-0809-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
81 Draga M, Madgett EB, Vandenberg CJ, du Plessis D, Kaufmann A, Werler P, Chakraborty P, Lowndes NF, Hiom K. BRCA1 Is Required for Maintenance of Phospho-Chk1 and G2/M Arrest during DNA Cross-Link Repair in DT40 Cells. Mol Cell Biol 2015;35:3829-40. [PMID: 26324327 DOI: 10.1128/MCB.01497-14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
82 Kast K, Rhiem K. Familial breast cancer - targeted therapy in secondary and tertiary prevention. Breast Care (Basel) 2015;10:27-31. [PMID: 25960722 DOI: 10.1159/000380756] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
83 Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Strychor S, Kiesel BF, Linden HM, Thompson JA, Swisher E, Chai X, Shepherd S, Giranda V, Specht JM. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. Clin Cancer Res 2016;22:2855-64. [PMID: 26801247 DOI: 10.1158/1078-0432.CCR-15-2137] [Cited by in Crossref: 42] [Cited by in F6Publishing: 27] [Article Influence: 8.4] [Reference Citation Analysis]
84 Biswas T, Efird JT, Prasad S, Jindal C, Walker PR. The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer. Oncotarget 2017;8:112712-9. [PMID: 29348858 DOI: 10.18632/oncotarget.22521] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
85 Zhang M, Zhang S, Wen Y, Wang Y, Wei Y, Liu H, Zhang D, Su J, Wang F, Zhang Y. DNA Methylation Patterns Can Estimate Nonequivalent Outcomes of Breast Cancer with the Same Receptor Subtypes. PLoS One 2015;10:e0142279. [PMID: 26550991 DOI: 10.1371/journal.pone.0142279] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
86 Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Muñoz M, Russnes HG, Helland A, Rye IH, Borresen-Dale AL, Maruyama R, van Oudenaarden A, Dowsett M, Jones RL, Reis-Filho J, Gascon P, Gönen M, Michor F, Polyak K. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep 2014;6:514-27. [PMID: 24462293 DOI: 10.1016/j.celrep.2013.12.041] [Cited by in Crossref: 182] [Cited by in F6Publishing: 154] [Article Influence: 26.0] [Reference Citation Analysis]
87 Goel AK, Nandy M, Sharma G. Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results. Indian J Med Paediatr Oncol 2010;31:76-8. [PMID: 21206711 DOI: 10.4103/0971-5851.73588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
88 Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they? Mol Oncol. 2010;4:192-208. [PMID: 20452298 DOI: 10.1016/j.molonc.2010.04.004] [Cited by in Crossref: 219] [Cited by in F6Publishing: 178] [Article Influence: 19.9] [Reference Citation Analysis]
89 Bilal E, Alexe G, Yao M, Cong L, Kulkarni A, Ginjala V, Toppmeyer D, Ganesan S, Bhanot G. Identification of the YES1 Kinase as a Therapeutic Target in Basal-Like Breast Cancers. Genes Cancer 2010;1:1063-73. [PMID: 21779430 DOI: 10.1177/1947601910395583] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
90 Zong B, Sun L, Peng Y, Wang Y, Yu Y, Lei J, Zhang Y, Guo S, Li K, Liu S. HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance. Oncol Rep 2021;46:138. [PMID: 34036395 DOI: 10.3892/or.2021.8089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
91 Zhu L, Liu J, Liang F, Rayner S, Xiong J. Predicting response to preoperative chemotherapy agents by identifying drug action on modeled microRNA regulation networks. PLoS One. 2014;9:e98140. [PMID: 24848634 DOI: 10.1371/journal.pone.0098140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
92 Nekulova M, Holcakova J, Gu X, Hrabal V, Galtsidis S, Orzol P, Liu Y, Logotheti S, Zoumpourlis V, Nylander K, Coates PJ, Vojtesek B. ΔNp63α expression induces loss of cell adhesion in triple-negative breast cancer cells. BMC Cancer 2016;16:782. [PMID: 27724925 DOI: 10.1186/s12885-016-2808-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
93 Ebrahimi Shahmabadi H, Movahedi F, Koohi Moftakhari Esfahani M, Alavi SE, Eslamifar A, Mohammadi Anaraki G, Akbarzadeh A. Efficacy of Cisplatin-loaded polybutyl cyanoacrylate nanoparticles on the glioblastoma. Tumour Biol 2014;35:4799-806. [PMID: 24443270 DOI: 10.1007/s13277-014-1630-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
94 Bergin ART, Loi S. Triple-negative breast cancer: recent treatment advances. F1000Res 2019;8:F1000 Faculty Rev-1342. [PMID: 31448088 DOI: 10.12688/f1000research.18888.1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 19.0] [Reference Citation Analysis]
95 Tacconi EM, Badie S, De Gregoriis G, Reisländer T, Lai X, Porru M, Folio C, Moore J, Kopp A, Baguña Torres J, Sneddon D, Green M, Dedic S, Lee JW, Batra AS, Rueda OM, Bruna A, Leonetti C, Caldas C, Cornelissen B, Brino L, Ryan A, Biroccio A, Tarsounas M. Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance. EMBO Mol Med 2019;11:e9982. [PMID: 31273933 DOI: 10.15252/emmm.201809982] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
96 Abramson VG, Mayer IA. Molecular Heterogeneity of Triple Negative Breast Cancer. Curr Breast Cancer Rep 2014;6:154-8. [PMID: 25419441 DOI: 10.1007/s12609-014-0152-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
97 Quist J, Mirza H, Cheang MCU, Telli ML, O'Shaughnessy JA, Lord CJ, Tutt ANJ, Grigoriadis A. A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics. Mol Cancer Ther 2019;18:204-12. [PMID: 30305342 DOI: 10.1158/1535-7163.MCT-18-0243] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
98 Liu M, Li Z, Yang J, Jiang Y, Chen Z, Ali Z, He N, Wang Z. Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment. Cell Prolif 2016;49:409-20. [PMID: 27312135 DOI: 10.1111/cpr.12266] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
99 Ferreira AR, Metzger-Filho O, Sarmento RMB, Bines J. Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02). Front Oncol 2017;7:329. [PMID: 29416986 DOI: 10.3389/fonc.2017.00329] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
100 Sai S, Vares G, Kim EH, Karasawa K, Wang B, Nenoi M, Horimoto Y, Hayashi M. Carbon ion beam combined with cisplatin effectively disrupts triple negative breast cancer stem-like cells in vitro. Mol Cancer 2015;14:166. [PMID: 26338199 DOI: 10.1186/s12943-015-0429-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
101 Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2016;22:3764-3773. [PMID: 26957554 DOI: 10.1158/1078-0432.ccr-15-2477] [Cited by in Crossref: 343] [Cited by in F6Publishing: 164] [Article Influence: 68.6] [Reference Citation Analysis]
102 Tan X, Fu Y, Chen L, Lee W, Lai Y, Rezaei K, Tabbara S, Latham P, Teal CB, Man YG, Siegel RS, Brem RF, Fu SW. miR-671-5p inhibits epithelial-to-mesenchymal transition by downregulating FOXM1 expression in breast cancer. Oncotarget 2016;7:293-307. [PMID: 26588055 DOI: 10.18632/oncotarget.6344] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 9.2] [Reference Citation Analysis]
103 Ory B, Ellisen LW. A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family cross-talk meets therapeutic opportunity. Oncotarget 2011;2:259-64. [PMID: 21436470 DOI: 10.18632/oncotarget.244] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
104 Rottenberg S, Disler C, Perego P. The rediscovery of platinum-based cancer therapy. Nat Rev Cancer 2021;21:37-50. [PMID: 33128031 DOI: 10.1038/s41568-020-00308-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 41.0] [Reference Citation Analysis]
105 Parmar V, Nair NS, Thakkar P, Chitkara G. Molecular Biology in the Breast Clinics-Current status and future perspectives. Indian J Surg Oncol 2021;12:7-20. [PMID: 33994723 DOI: 10.1007/s13193-019-00954-1] [Reference Citation Analysis]
106 Li C, Li X, Li G, Sun L, Zhang W, Jiang J, Ge Q. Identification of a prognosis‑associated signature associated with energy metabolism in triple‑negative breast cancer. Oncol Rep 2020;44:819-37. [PMID: 32582991 DOI: 10.3892/or.2020.7657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
107 Choi YL, Oh E, Park S, Kim Y, Park YH, Song K, Cho EY, Hong YC, Choi JS, Lee JE, Kim JH, Nam SJ, Im YH, Yang JH, Shin YK. Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. BMC Cancer 2010;10:507. [PMID: 20860845 DOI: 10.1186/1471-2407-10-507] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
108 Garcia E, Luna I, Persad KL, Agopsowicz K, Jay DA, West FG, Hitt MM, Persad S. Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition. Sci Rep 2021;11:11757. [PMID: 34083676 DOI: 10.1038/s41598-021-91344-7] [Reference Citation Analysis]
109 Menghi F, Inaki K, Woo X, Kumar PA, Grzeda KR, Malhotra A, Yadav V, Kim H, Marquez EJ, Ucar D, Shreckengast PT, Wagner JP, MacIntyre G, Murthy Karuturi KR, Scully R, Keck J, Chuang JH, Liu ET. The tandem duplicator phenotype as a distinct genomic configuration in cancer. Proc Natl Acad Sci U S A 2016;113:E2373-82. [PMID: 27071093 DOI: 10.1073/pnas.1520010113] [Cited by in Crossref: 75] [Cited by in F6Publishing: 53] [Article Influence: 15.0] [Reference Citation Analysis]
110 Parkes A, Arun BK, Litton JK. Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes. Oncologist 2017;22:655-66. [PMID: 28469042 DOI: 10.1634/theoncologist.2016-0430] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
111 Fisher CS, Ma CX, Gillanders WE, Aft RL, Eberlein TJ, Gao F, Margenthaler JA. Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response. Ann Surg Oncol 2012;19:253-8. [PMID: 21725686 DOI: 10.1245/s10434-011-1877-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
112 Li Q, Wang J, Mu Y, Zhang T, Han Y, Wang J, Li Q, Luo Y, Ma F, Fan Y, Zhang P, Xu B. Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer. Chin J Cancer Res 2020;32:485-96. [PMID: 32963461 DOI: 10.21147/j.issn.1000-9604.2020.04.06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Wang Y, Krais JJ, Bernhardy AJ, Nicolas E, Cai KQ, Harrell MI, Kim HH, George E, Swisher EM, Simpkins F, Johnson N. RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance. J Clin Invest 2016;126:3145-57. [PMID: 27454289 DOI: 10.1172/JCI87033] [Cited by in Crossref: 48] [Cited by in F6Publishing: 30] [Article Influence: 9.6] [Reference Citation Analysis]
114 Heimer BW, Tam BE, Sikes HD. Characterization and directed evolution of a methyl-binding domain protein for high-sensitivity DNA methylation analysis. Protein Eng Des Sel 2015;28:543-51. [PMID: 26384511 DOI: 10.1093/protein/gzv046] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
115 El Guerrab A, Bamdad M, Kwiatkowski F, Bignon YJ, Penault-Llorca F, Aubel C. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer. Oncotarget 2016;7:73618-37. [PMID: 27655662 DOI: 10.18632/oncotarget.12037] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 12.3] [Reference Citation Analysis]
116 Arnedos M, Bihan C, Delaloge S, Andre F. Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol 2012;4:195-210. [PMID: 22754593 DOI: 10.1177/1758834012444711] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
117 Misra S, Zhang X, Wani NA, Sizemore S, Ray A. Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment. Oncotarget 2020;11:784-800. [PMID: 32166000 DOI: 10.18632/oncotarget.27485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Sharma P. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer. Curr Treat Options Oncol 2018;19:22. [PMID: 29656345 DOI: 10.1007/s11864-018-0539-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
119 Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist. 2013;18:123-133. [PMID: 23404817 DOI: 10.1634/theoncologist.2012-0397] [Cited by in Crossref: 313] [Cited by in F6Publishing: 279] [Article Influence: 39.1] [Reference Citation Analysis]
120 Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J, Sotiriou C. A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst 2012;104:311-25. [PMID: 22262870 DOI: 10.1093/jnci/djr545] [Cited by in Crossref: 211] [Cited by in F6Publishing: 163] [Article Influence: 23.4] [Reference Citation Analysis]
121 Dawood S. Triple-negative breast cancer: epidemiology and management options. Drugs 2010;70:2247-58. [PMID: 21080741 DOI: 10.2165/11538150-000000000-00000] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 7.3] [Reference Citation Analysis]
122 Song W, Tang L, Xu Y, Xu J, Zhang W, Xie H, Wang S, Guan X. PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer. Sci Rep 2017;7:42319. [PMID: 28176879 DOI: 10.1038/srep42319] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
123 Bisso A, Faleschini M, Zampa F, Capaci V, De Santa J, Santarpia L, Piazza S, Cappelletti V, Daidone M, Agami R, Del Sal G. Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle 2013;12:1679-87. [PMID: 23656790 DOI: 10.4161/cc.24757] [Cited by in Crossref: 80] [Cited by in F6Publishing: 68] [Article Influence: 10.0] [Reference Citation Analysis]
124 Tiong KH, Tan BS, Choo HL, Chung FF, Hii LW, Tan SH, Khor NT, Wong SF, See SJ, Tan YF, Rosli R, Cheong SK, Leong CO. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival. Oncotarget 2016;7:57633-50. [PMID: 27192118 DOI: 10.18632/oncotarget.9328] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 13.7] [Reference Citation Analysis]
125 Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer 2017;3:49. [PMID: 29238749 DOI: 10.1038/s41523-017-0052-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
126 Sharma P. Biology and Management of Patients With Triple-Negative Breast Cancer. Oncologist 2016;21:1050-62. [PMID: 27401886 DOI: 10.1634/theoncologist.2016-0067] [Cited by in Crossref: 87] [Cited by in F6Publishing: 82] [Article Influence: 17.4] [Reference Citation Analysis]
127 Yadav S, Sehrawat A, Eroglu Z, Somlo G, Hickey R, Yadav S, Liu X, Awasthi YC, Awasthi S. Role of SMC1 in overcoming drug resistance in triple negative breast cancer. PLoS One 2013;8:e64338. [PMID: 23717600 DOI: 10.1371/journal.pone.0064338] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
128 Nwaogu IY, Fayanju OM, Jeffe DB, Margenthaler JA. Predictors of pathological complete response to neoadjuvant chemotherapy in stage II and III breast cancer: The impact of chemotherapeutic regimen. Mol Clin Oncol 2015;3:1117-22. [PMID: 26623062 DOI: 10.3892/mco.2015.579] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
129 Long M, Wu J, Hao J, Liu W, Tang Y, Li X, Su H, Qiu W. Selenocystine-induced cell apoptosis and S-phase arrest inhibit human triple-negative breast cancer cell proliferation. In Vitro Cell Dev Biol Anim 2015;51:1077-84. [PMID: 26194802 DOI: 10.1007/s11626-015-9937-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
130 Palma G, Frasci G, Chirico A, Esposito E, Siani C, Saturnino C, Arra C, Ciliberto G, Giordano A, D'Aiuto M. Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget 2015;6:26560-74. [PMID: 26387133 DOI: 10.18632/oncotarget.5306] [Cited by in Crossref: 88] [Cited by in F6Publishing: 85] [Article Influence: 17.6] [Reference Citation Analysis]
131 Mayer EL, Abramson V, Jankowitz R, Falkson C, Marcom PK, Traina T, Carey L, Rimawi M, Specht J, Miller K, Stearns V, Tung N, Perou C, Richardson AL, Componeschi K, Trippa L, Tan-Wasielewski Z, Timms K, Krop I, Wolff AC, Winer EP. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Ann Oncol 2020;31:1518-25. [PMID: 32798689 DOI: 10.1016/j.annonc.2020.08.2064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
132 Witkiewicz AK, Balaji U, Knudsen ES. Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers. Clin Cancer Res 2014;20:4837-48. [PMID: 25047707 DOI: 10.1158/1078-0432.CCR-14-0885] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
133 Aly A, Ganesan S. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. J Mol Cell Biol 2011;3:66-74. [PMID: 21278454 DOI: 10.1093/jmcb/mjq055] [Cited by in Crossref: 74] [Cited by in F6Publishing: 63] [Article Influence: 7.4] [Reference Citation Analysis]
134 Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev LT, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA, Park JW, Marton LJ, Wolf DM, Collisson EA, Neve RM, Mills GB, Speed TP, Feiler HS, Wooster RF, Haussler D, Stuart JM, Gray JW, Spellman PT. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A 2012;109:2724-9. [PMID: 22003129 DOI: 10.1073/pnas.1018854108] [Cited by in Crossref: 321] [Cited by in F6Publishing: 268] [Article Influence: 32.1] [Reference Citation Analysis]
135 Sabatier R, Finetti P, Guille A, Adelaide J, Chaffanet M, Viens P, Birnbaum D, Bertucci F. Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. Mol Cancer 2014;13:228. [PMID: 25277734 DOI: 10.1186/1476-4598-13-228] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 9.6] [Reference Citation Analysis]
136 Kolacinska A, Fendler W, Szemraj J, Szymanska B, Borowska-Garganisz E, Nowik M, Chalubinska J, Kubiak R, Pawlowska Z, Blasinska-Morawiec M, Potemski P, Jeziorski A, Morawiec Z. Gene expression and pathologic response to neoadjuvant chemotherapy in breast cancer. Mol Biol Rep 2012;39:7435-41. [PMID: 22318550 DOI: 10.1007/s11033-012-1576-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
137 Mehner C, Hockla A, Miller E, Ran S, Radisky DC, Radisky ES. Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget 2014;5:2736-49. [PMID: 24811362 DOI: 10.18632/oncotarget.1932] [Cited by in Crossref: 181] [Cited by in F6Publishing: 171] [Article Influence: 30.2] [Reference Citation Analysis]
138 Ancot F, Arcand SL, Mes-Masson AM, Provencher DM, Tonin PN. Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population. Oncol Lett 2015;9:2787-90. [PMID: 26137147 DOI: 10.3892/ol.2015.3123] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
139 Sun W, Li C, Liu M, Liu W, Yang C, Cai LI. Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide. Oncol Lett 2016;11:2320-6. [PMID: 26998170 DOI: 10.3892/ol.2016.4176] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
140 Alkahtani S, Alarifi S, Albasher G, Al-Zharani M, Aljarba NH, Almarzoug MH, Alhoshani NM, Al-Johani NS, Alothaid H, Alkahtane AA. Poly Lactic-Co-Glycolic Acid- (PLGA-) Loaded Nanoformulation of Cisplatin as a Therapeutic Approach for Breast Cancers. Oxid Med Cell Longev 2021;2021:5834418. [PMID: 34257812 DOI: 10.1155/2021/5834418] [Reference Citation Analysis]
141 Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33:13-21. [PMID: 25092775 DOI: 10.1200/jco.2014.57.0572] [Cited by in Crossref: 458] [Cited by in F6Publishing: 226] [Article Influence: 65.4] [Reference Citation Analysis]
142 Elimimian EB, Samuel TA, Liang H, Elson L, Bilani N, Nahleh ZA. Clinical and Demographic Factors, Treatment Patterns, and Overall Survival Associated With Rare Triple-Negative Breast Carcinomas in the US. JAMA Netw Open 2021;4:e214123. [PMID: 33844001 DOI: 10.1001/jamanetworkopen.2021.4123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Yu Z, Cao W, Ren Y, Zhang Q, Liu J. ATPase copper transporter A, negatively regulated by miR-148a-3p, contributes to cisplatin resistance in breast cancer cells. Clin Transl Med 2020;10:57-73. [PMID: 32508020 DOI: 10.1002/ctm2.19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
144 Ayala-Orozco C, Urban C, Knight MW, Urban AS, Neumann O, Bishnoi SW, Mukherjee S, Goodman AM, Charron H, Mitchell T, Shea M, Roy R, Nanda S, Schiff R, Halas NJ, Joshi A. Au nanomatryoshkas as efficient near-infrared photothermal transducers for cancer treatment: benchmarking against nanoshells. ACS Nano 2014;8:6372-81. [PMID: 24889266 DOI: 10.1021/nn501871d] [Cited by in Crossref: 256] [Cited by in F6Publishing: 177] [Article Influence: 36.6] [Reference Citation Analysis]
145 Chen MB, Zhu YQ, Xu JY, Wang LQ, Liu CY, Ji ZY, Lu PH. Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. PLoS One 2012;7:e39655. [PMID: 22768103 DOI: 10.1371/journal.pone.0039655] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
146 Donovan MG, Selmin OI, Stillwater BJ, Neumayer LA, Romagnolo DF. Do Olive and Fish Oils of the Mediterranean Diet Have a Role in Triple Negative Breast Cancer Prevention and Therapy? An Exploration of Evidence in Cells and Animal Models. Front Nutr 2020;7:571455. [PMID: 33123546 DOI: 10.3389/fnut.2020.571455] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
147 Deans AJ, West SC. DNA interstrand crosslink repair and cancer. Nat Rev Cancer 2011;11:467-80. [PMID: 21701511 DOI: 10.1038/nrc3088] [Cited by in Crossref: 632] [Cited by in F6Publishing: 527] [Article Influence: 63.2] [Reference Citation Analysis]
148 Cancello G, Montagna E. Treatment of breast cancer in young women: do we need more aggressive therapies? J Thorac Dis 2013;5 Suppl 1:S47-54. [PMID: 23819027 DOI: 10.3978/j.issn.2072-1439.2013.06.10] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
149 Liu RZ, Garcia E, Glubrecht DD, Poon HY, Mackey JR, Godbout R. CRABP1 is associated with a poor prognosis in breast cancer: adding to the complexity of breast cancer cell response to retinoic acid. Mol Cancer 2015;14:129. [PMID: 26142905 DOI: 10.1186/s12943-015-0380-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
150 Chowdhury P, Ghosh U, Samanta K, Jaggi M, Chauhan SC, Yallapu MM. Bioactive nanotherapeutic trends to combat triple negative breast cancer. Bioact Mater 2021;6:3269-87. [PMID: 33778204 DOI: 10.1016/j.bioactmat.2021.02.037] [Reference Citation Analysis]
151 Burgess M, Puhalla S. BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different. Front Oncol 2014;4:19. [PMID: 24579064 DOI: 10.3389/fonc.2014.00019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
152 Watkins J, Weekes D, Shah V, Gazinska P, Joshi S, Sidhu B, Gillett C, Pinder S, Vanoli F, Jasin M, Mayrhofer M, Isaksson A, Cheang MC, Mirza H, Frankum J, Lord CJ, Ashworth A, Vinayak S, Ford JM, Telli ML, Grigoriadis A, Tutt AN. Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. Cancer Discov 2015;5:488-505. [PMID: 25770156 DOI: 10.1158/2159-8290.CD-14-1092] [Cited by in Crossref: 66] [Cited by in F6Publishing: 37] [Article Influence: 11.0] [Reference Citation Analysis]
153 Austin D, Hamilton N, Elshimali Y, Pietras R, Wu Y, Vadgama J. Estrogen receptor-beta is a potential target for triple negative breast cancer treatment. Oncotarget 2018;9:33912-30. [PMID: 30338035 DOI: 10.18632/oncotarget.26089] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
154 Sulaiman A, McGarry S, Chambers J, Al-Kadi E, Phan A, Li L, Mediratta K, Dimitroulakos J, Addison C, Li X, Wang L. Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells. Int J Mol Sci 2020;21:E5788. [PMID: 32806648 DOI: 10.3390/ijms21165788] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Hansen J, Iyengar R. Computation as the mechanistic bridge between precision medicine and systems therapeutics. Clin Pharmacol Ther 2013;93:117-28. [PMID: 23212109 DOI: 10.1038/clpt.2012.199] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
156 Diana A, Carlino F, Franzese E, Oikonomidou O, Criscitiello C, De Vita F, Ciardiello F, Orditura M. Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes. Cancers (Basel) 2020;12:E819. [PMID: 32235297 DOI: 10.3390/cancers12040819] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 19.0] [Reference Citation Analysis]
157 Guglielmi C, Scarpitta R, Gambino G, Conti E, Bellè F, Tancredi M, Cervelli T, Falaschi E, Cosini C, Aretini P, Congregati C, Marino M, Patruno M, Pilato B, Spina F, Balestrino L, Tenedini E, Carnevali I, Cortesi L, Tagliafico E, Tibiletti MG, Tommasi S, Ghilli M, Vivanet C, Galli A, Caligo MA. Detection of Germline Variants in 450 Breast/Ovarian Cancer Families with a Multi-Gene Panel Including Coding and Regulatory Regions. Int J Mol Sci 2021;22:7693. [PMID: 34299313 DOI: 10.3390/ijms22147693] [Reference Citation Analysis]
158 Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, Wu J, Liu GY, Di GH, Zeng XH, He PQ, Wu KJ, Hou YF, Wang J, Wang C, Zhuang ZG, Song CG, Lin XY, Toss A, Ricci F, Shen ZZ, Shao ZM. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol 2020;6:1390-6. [PMID: 32789480 DOI: 10.1001/jamaoncol.2020.2965] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
159 Jin X, Jiang YZ, Chen S, Yu KD, Ma D, Sun W, Shao ZM, Di GH. A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer. BMC Cancer 2016;16:606. [PMID: 27495967 DOI: 10.1186/s12885-016-2652-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
160 Minami CA, Chung DU, Chang HR. Management options in triple-negative breast cancer. Breast Cancer (Auckl) 2011;5:175-99. [PMID: 21863131 DOI: 10.4137/BCBCR.S6562] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
161 Cocco S, Piezzo M, Calabrese A, Cianniello D, Caputo R, Lauro VD, Fusco G, Gioia GD, Licenziato M, De Laurentiis M. Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. Int J Mol Sci 2020;21:E4579. [PMID: 32605126 DOI: 10.3390/ijms21134579] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
162 Branham MT, Campoy E, Laurito S, Branham R, Urrutia G, Orozco J, Gago F, Urrutia R, Roqué M. Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer. Breast Cancer Res Treat 2016;155:13-23. [PMID: 26610810 DOI: 10.1007/s10549-015-3648-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
163 Holstege H, Horlings HM, Velds A, Langerød A, Børresen-Dale AL, van de Vijver MJ, Nederlof PM, Jonkers J. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. BMC Cancer 2010;10:654. [PMID: 21118481 DOI: 10.1186/1471-2407-10-654] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
164 Sharifi-Noghabi H, Peng S, Zolotareva O, Collins CC, Ester M. AITL: Adversarial Inductive Transfer Learning with input and output space adaptation for pharmacogenomics. Bioinformatics 2020;36:i380-8. [PMID: 32657371 DOI: 10.1093/bioinformatics/btaa442] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
165 Parachoniak CA, Rankin A, Gaffney B, Hartmaier R, Spritz D, Erlich RL, Miller VA, Morosini D, Stephens P, Ross JS, Keech J Jr, Chmielecki J. Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant. Cold Spring Harb Mol Case Stud 2017;3:a000778. [PMID: 28550065 DOI: 10.1101/mcs.a000778] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
166 Miow QH, Tan TZ, Ye J, Lau JA, Yokomizo T, Thiery JP, Mori S. Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene 2015;34:1899-907. [PMID: 24858042 DOI: 10.1038/onc.2014.136] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 10.0] [Reference Citation Analysis]
167 Brewster AM, Chavez-MacGregor M, Brown P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol 2014;15:e625-34. [PMID: 25456381 DOI: 10.1016/S1470-2045(14)70364-X] [Cited by in Crossref: 111] [Cited by in F6Publishing: 69] [Article Influence: 15.9] [Reference Citation Analysis]
168 Geeleher P, Cox NJ, Huang RS. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol 2014;15:R47. [PMID: 24580837 DOI: 10.1186/gb-2014-15-3-r47] [Cited by in Crossref: 228] [Cited by in F6Publishing: 169] [Article Influence: 32.6] [Reference Citation Analysis]
169 Stecklein SR, Kumaraswamy E, Behbod F, Wang W, Chaguturu V, Harlan-Williams LM, Jensen RA. BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation. Proc Natl Acad Sci U S A 2012;109:13650-5. [PMID: 22869732 DOI: 10.1073/pnas.1203326109] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 9.0] [Reference Citation Analysis]
170 Jhan JR, Andrechek ER. Triple-negative breast cancer and the potential for targeted therapy. Pharmacogenomics 2017;18:1595-609. [PMID: 29095114 DOI: 10.2217/pgs-2017-0117] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 17.3] [Reference Citation Analysis]
171 Gao M, Wang T, Ji L, Bai S, Tian L, Song H. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer. Front Immunol 2020;11:366. [PMID: 32194569 DOI: 10.3389/fimmu.2020.00366] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
172 Nhukeaw T, Temboot P, Hansongnern K, Ratanaphan A. Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine. BMC Cancer 2014;14:73. [PMID: 24507701 DOI: 10.1186/1471-2407-14-73] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
173 Seldin L, Macara IG. DNA Damage Promotes Epithelial Hyperplasia and Fate Mis-specification via Fibroblast Inflammasome Activation. Dev Cell 2020;55:558-573.e6. [PMID: 33058780 DOI: 10.1016/j.devcel.2020.09.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
174 Peshkin BN, Alabek ML, Isaacs C. BRCA1/2 mutations and triple negative breast cancers. Breast Dis. 2010;32:25-33. [PMID: 21778580 DOI: 10.3233/bd-2010-0306] [Cited by in Crossref: 68] [Cited by in F6Publishing: 48] [Article Influence: 7.6] [Reference Citation Analysis]
175 Verma S, Provencher L, Dent R. Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. Curr Oncol 2011;18:180-90. [PMID: 21874117 DOI: 10.3747/co.v18i4.913] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
176 Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, Tomlinson I, Hanby AM, Speirs V, Richardson AL, Birkbak NJ, Eklund AC, Downward J, Kschischo M, Szallasi Z, Swanton C. Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol Biomarkers Prev 2011;20:2183-94. [PMID: 21784954 DOI: 10.1158/1055-9965.EPI-11-0343] [Cited by in Crossref: 101] [Cited by in F6Publishing: 69] [Article Influence: 10.1] [Reference Citation Analysis]
177 Xu J, Prosperi JR, Choudhury N, Olopade OI, Goss KH. β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLoS One 2015;10:e0117097. [PMID: 25658419 DOI: 10.1371/journal.pone.0117097] [Cited by in Crossref: 85] [Cited by in F6Publishing: 87] [Article Influence: 14.2] [Reference Citation Analysis]
178 Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, Timms K, Abkevich V, Schackmann EA, Wapnir IL, Carlson RW, Chang PJ, Sparano JA, Head B, Goldstein LJ, Haley B, Dakhil SR, Reid JE, Hartman AR, Manola J, Ford JM. Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. J Clin Oncol 2015;33:1895-901. [PMID: 25847929 DOI: 10.1200/JCO.2014.57.0085] [Cited by in Crossref: 145] [Cited by in F6Publishing: 79] [Article Influence: 24.2] [Reference Citation Analysis]
179 Arslan C, Yalcin S. Current and future systemic treatment options in metastatic pancreatic cancer. J Gastrointest Oncol. 2014;5:280-295. [PMID: 25083302 DOI: 10.3978/j.issn.2078-6891.2014.030] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
180 Xu Y, Lin Y, Wang Y, Zhou L, Xu S, Wu Y, Peng J, Zhang J, Yin W, Lu J. Association of Neo-Family History Score with pathological complete response, safety, and survival outcomes in patients with breast cancer receiving neoadjuvant platinum-based chemotherapy: An exploratory analysis of two prospective trials. EClinicalMedicine 2021;38:101031. [PMID: 34337367 DOI: 10.1016/j.eclinm.2021.101031] [Reference Citation Analysis]
181 Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2015;33:1902-1909. [PMID: 25847936 DOI: 10.1200/jco.2014.57.6660] [Cited by in Crossref: 237] [Cited by in F6Publishing: 126] [Article Influence: 39.5] [Reference Citation Analysis]
182 Stefansson OA, Jonasson JG, Olafsdottir K, Hilmarsdottir H, Olafsdottir G, Esteller M, Johannsson OT, Eyfjord JE. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. Epigenetics 2011;6:638-49. [PMID: 21593597 DOI: 10.4161/epi.6.5.15667] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 6.5] [Reference Citation Analysis]
183 Yang J, Han J, Tian M, Tian K, Liao W, Yan X. Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. Cancer Manag Res 2020;12:12905-13. [PMID: 33364838 DOI: 10.2147/CMAR.S284556] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
184 Huang Y, Wu H, Li X. Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer. Cancer Cell Int. 2020;20:501. [PMID: 33061853 DOI: 10.1186/s12935-020-01597-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
185 Warmoes M, Jaspers JE, Xu G, Sampadi BK, Pham TV, Knol JC, Piersma SR, Boven E, Jonkers J, Rottenberg S, Jimenez CR. Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance. Mol Cell Proteomics 2013;12:1319-34. [PMID: 23397111 DOI: 10.1074/mcp.M112.024182] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
186 Liu J, Chen X, Ward T, Pegram M, Shen K. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer. Tumour Biol 2016;37:9825-35. [PMID: 26810188 DOI: 10.1007/s13277-015-4650-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
187 Turner NC, Tutt AN. Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence? Breast Cancer Res 2012;14:115. [PMID: 23146216 DOI: 10.1186/bcr3332] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
188 Pandy JGP, Balolong-Garcia JC, Cruz-Ordinario MVB, Que FVF. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review. BMC Cancer 2019;19:1065. [PMID: 31703646 DOI: 10.1186/s12885-019-6253-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 15.5] [Reference Citation Analysis]
189 Khalaf D, Hilton JF, Clemons M, Azoulay L, Yin H, Vandermeer L, Dent S, Hopkins S, Bouganim N. Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. Oncol Lett 2014;7:866-70. [PMID: 24527094 DOI: 10.3892/ol.2014.1782] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
190 Sharma P, Stecklein SR, Kimler BF, Sethi G, Petroff BK, Phillips TA, Tawfik OW, Godwin AK, Jensen RA. The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer. J Cancer Ther Res 2014;3:1-11. [PMID: 25177489 DOI: 10.7243/2049-7962-3-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
191 Paul A, Gunewardena S, Stecklein SR, Saha B, Parelkar N, Danley M, Rajendran G, Home P, Ray S, Jokar I, Vielhauer GA, Jensen RA, Tawfik O, Paul S. PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis. Cell Death Differ 2014;21:1469-81. [PMID: 24786829 DOI: 10.1038/cdd.2014.62] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
192 Witte T, Plass C, Gerhauser C. Pan-cancer patterns of DNA methylation. Genome Med. 2014;6:66. [PMID: 25473433 DOI: 10.1186/s13073-014-0066-6] [Cited by in Crossref: 103] [Cited by in F6Publishing: 79] [Article Influence: 14.7] [Reference Citation Analysis]
193 Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet. 2012;13:679-692. [PMID: 22945394 DOI: 10.1038/nrg3270] [Cited by in Crossref: 529] [Cited by in F6Publishing: 436] [Article Influence: 58.8] [Reference Citation Analysis]
194 Zhou L, Xu S, Yin W, Lin Y, Du Y, Jiang Y, Wang Y, Zhang J, Wu Z, Lu J. Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study. Oncotarget 2017;8:79305-14. [PMID: 29108309 DOI: 10.18632/oncotarget.17954] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
195 Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750-2767. [PMID: 21633166 DOI: 10.1172/jci45014] [Cited by in Crossref: 2695] [Cited by in F6Publishing: 1686] [Article Influence: 269.5] [Reference Citation Analysis]
196 Aulas A, Finetti P, Lyons SM, Bertucci F, Birnbaum D, Acquaviva C, Mamessier E. Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins? Cancers (Basel) 2020;12:E2470. [PMID: 32882814 DOI: 10.3390/cancers12092470] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
197 Saraiva DP, Guadalupe Cabral M, Jacinto A, Braga S. How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. ESMO Open 2017;2:e000208. [PMID: 29018573 DOI: 10.1136/esmoopen-2017-000208] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
198 Mori H, Kubo M, Nishimura R, Osako T, Arima N, Okumura Y, Okido M, Yamada M, Kai M, Kishimoto J, Miyazaki T, Oda Y, Otsuka T, Nakamura M. BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer. PLoS One 2016;11:e0167016. [PMID: 27977696 DOI: 10.1371/journal.pone.0167016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
199 Liu M, Mo QG, Wei CY, Qin QH, Huang Z, He J. Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis. Oncol Lett 2013;5:983-91. [PMID: 23426861 DOI: 10.3892/ol.2012.1093] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
200 Guarneri V, Dieci MV, Conte P. Relapsed triple-negative breast cancer: challenges and treatment strategies. Drugs 2013;73:1257-65. [PMID: 23842749 DOI: 10.1007/s40265-013-0091-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
201 Weigman VJ, Chao HH, Shabalin AA, He X, Parker JS, Nordgard SH, Grushko T, Huo D, Nwachukwu C, Nobel A, Kristensen VN, Børresen-Dale AL, Olopade OI, Perou CM. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat 2012;133:865-80. [PMID: 22048815 DOI: 10.1007/s10549-011-1846-y] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 7.1] [Reference Citation Analysis]
202 Chen XS, Yuan Y, Garfield DH, Wu JY, Huang O, Shen KW. Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis. PLoS One 2014;9:e108405. [PMID: 25247558 DOI: 10.1371/journal.pone.0108405] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
203 Nekulova M, Holcakova J, Coates P, Vojtesek B. The role of p63 in cancer, stem cells and cancer stem cells. Cell Mol Biol Lett 2011;16:296-327. [PMID: 21442444 DOI: 10.2478/s11658-011-0009-9] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 5.6] [Reference Citation Analysis]
204 Palomba G, Atzori F, Budroni M, Ombra M, Cossu A, Sini M, Pusceddu V, Massidda B, Frau B, Notari F, Ionta M, Palmieri G. ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy. J Transl Med 2014;12:272. [PMID: 25253066 DOI: 10.1186/s12967-014-0272-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
205 Maachani UB, Kramp T, Hanson R, Zhao S, Celiku O, Shankavaram U, Colombo R, Caplen NJ, Camphausen K, Tandle A. Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins. Mol Cancer Res. 2015;13:852-862. [PMID: 25722303 DOI: 10.1158/1541-7786.mcr-14-0462-t] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
206 Lee MY, Moreno CS, Saavedra HI. E2F activators signal and maintain centrosome amplification in breast cancer cells. Mol Cell Biol. 2014;34:2581-2599. [PMID: 24797070 DOI: 10.1128/mcb.01688-13] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
207 Sonnenblick A, Venet D, Brohée S, Pondé N, Sotiriou C. pAKT pathway activation is associated with PIK3CA mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation. NPJ Breast Cancer 2019;5:7. [PMID: 30729154 DOI: 10.1038/s41523-019-0102-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
208 Elaimy AL, Amante JJ, Zhu LJ, Wang M, Walmsley CS, FitzGerald TJ, Goel HL, Mercurio AM. The VEGF receptor neuropilin 2 promotes homologous recombination by stimulating YAP/TAZ-mediated Rad51 expression. Proc Natl Acad Sci U S A 2019;116:14174-80. [PMID: 31235595 DOI: 10.1073/pnas.1821194116] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
209 Clark O, Botrel TE, Paladini L, Ferreira MB. Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis. Core Evid 2014;9:1-11. [PMID: 24476748 DOI: 10.2147/CE.S52197] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
210 Kim D, Jung W, Koo JS. The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes. J Korean Med Sci 2011;26:352-9. [PMID: 21394302 DOI: 10.3346/jkms.2011.26.3.352] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
211 Lønning PE. Molecular basis for therapy resistance. Mol Oncol 2010;4:284-300. [PMID: 20466604 DOI: 10.1016/j.molonc.2010.04.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
212 Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232:142-150. [PMID: 24114677 DOI: 10.1002/path.4280] [Cited by in Crossref: 227] [Cited by in F6Publishing: 212] [Article Influence: 32.4] [Reference Citation Analysis]
213 Gass P, Lux MP, Rauh C, Hein A, Bani MR, Fiessler C, Hartmann A, Häberle L, Pretscher J, Erber R, Wachter DL, Schulz-Wendtland R, Beckmann MW, Fasching PA, Wunderle M. Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. BMC Cancer 2018;18:1051. [PMID: 30373556 DOI: 10.1186/s12885-018-4925-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
214 Santana-Davila R, Perez EA. Treatment options for patients with triple-negative breast cancer. J Hematol Oncol 2010;3:42. [PMID: 20979652 DOI: 10.1186/1756-8722-3-42] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
215 Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM. Therapies for triple negative breast cancer. Expert Opin Pharmacother 2015;16:983-98. [PMID: 25881743 DOI: 10.1517/14656566.2015.1032246] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 8.8] [Reference Citation Analysis]
216 Ablain J, Poirot B, Esnault C, Lehmann-Che J, de Thé H. p53 as an Effector or Inhibitor of Therapy Response. Cold Spring Harb Perspect Med 2015;6:a026260. [PMID: 26637438 DOI: 10.1101/cshperspect.a026260] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
217 Clark CC, Weitzel JN, O'Connor TR. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol Cancer Ther 2012;11:1948-58. [PMID: 22778154 DOI: 10.1158/1535-7163.MCT-11-0597] [Cited by in Crossref: 53] [Cited by in F6Publishing: 21] [Article Influence: 5.9] [Reference Citation Analysis]
218 Tang Y, Zhu L, Li Y, Ji J, Li J, Yuan F, Wang D, Chen W, Huang O, Chen X, Wu J, Shen K, Loo WT, Chow LW. Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer. J Transl Med 2012;10 Suppl 1:S4. [PMID: 23046633 DOI: 10.1186/1479-5876-10-S1-S4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
219 Lemmo S, Atefi E, Luker GD, Tavana H. Optimization of Aqueous Biphasic Tumor Spheroid Microtechnology for Anti-Cancer Drug Testing in 3D Culture. Cell Mol Bioeng 2014;7:344-54. [PMID: 25221631 DOI: 10.1007/s12195-014-0349-4] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 6.9] [Reference Citation Analysis]
220 Son J, Lee SE, Kim EK, Kim S. Prediction of breast cancer molecular subtypes using radiomics signatures of synthetic mammography from digital breast tomosynthesis. Sci Rep 2020;10:21566. [PMID: 33299040 DOI: 10.1038/s41598-020-78681-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
221 Atipairin A, Ratanaphan A. In Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein. Breast Cancer (Auckl) 2011;5:201-8. [PMID: 22084573 DOI: 10.4137/BCBCR.S8184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
222 Lips EH, Mulder L, Oonk A, van der Kolk LE, Hogervorst FB, Imholz AL, Wesseling J, Rodenhuis S, Nederlof PM. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer 2013;108:2172-7. [PMID: 23558900 DOI: 10.1038/bjc.2013.144] [Cited by in Crossref: 131] [Cited by in F6Publishing: 125] [Article Influence: 16.4] [Reference Citation Analysis]
223 Tariq K, Rana F. TNBC vs. Non-TNBC: A Five-Year Retrospective Review of Differences in Mean Age, Family History, Smoking History and Stage at Diagnosis at an Inner City University Program. World J Oncol 2013;4:241-7. [PMID: 29147364 DOI: 10.4021/wjon738w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
224 Vaklavas C, Forero-Torres A. How do I treat "triple-negative" disease. Curr Treat Options Oncol 2011;12:369-88. [PMID: 22048876 DOI: 10.1007/s11864-011-0168-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
225 Qian J, Chen H, Ji X, Eisenberg R, Chakravarthy AB, Mayer IA, Massion PP. A 3q gene signature associated with triple negative breast cancer organ specific metastasis and response to neoadjuvant chemotherapy. Sci Rep 2017;7:45828. [PMID: 28387221 DOI: 10.1038/srep45828] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
226 Toffoli S, Bar I, Abdel-Sater F, Delrée P, Hilbert P, Cavallin F, Moreau F, Van Criekinge W, Lacroix-Triki M, Campone M, Martin AL, Roché H, Machiels JP, Carrasco J, Canon JL. Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer. Breast Cancer Res 2014;16:466. [PMID: 25416589 DOI: 10.1186/s13058-014-0466-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
227 Sun Y, Zhang W, Chen Y, Ma Q, Wei J, Liu Q. Identifying anti-cancer drug response related genes using an integrative analysis of transcriptomic and genomic variations with cell line-based drug perturbations. Oncotarget 2016;7:9404-19. [PMID: 26824188 DOI: 10.18632/oncotarget.7012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
228 Wu X, Tang P, Li S, Wang S, Liang Y, Zhong L, Ren L, Zhang T, Zhang Y. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer. Nat Commun 2018;9:832. [PMID: 29483583 DOI: 10.1038/s41467-018-03210-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
229 Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, Tan P, Tan IB, Richardson AL, Szallasi Z, Swanton C. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res 2011;71:3447-52. [PMID: 21270108 DOI: 10.1158/0008-5472.CAN-10-3667] [Cited by in Crossref: 224] [Cited by in F6Publishing: 134] [Article Influence: 22.4] [Reference Citation Analysis]
230 Godet I, Gilkes DM. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Ther 2017;4. [PMID: 28706734 DOI: 10.15761/ICST.1000228] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 9.5] [Reference Citation Analysis]
231 Rodríguez Bautista R, Ortega Gómez A, Hidalgo Miranda A, Zentella Dehesa A, Villarreal-Garza C, Ávila-Moreno F, Arrieta O. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer. Clin Epigenetics 2018;10:88. [PMID: 29983835 DOI: 10.1186/s13148-018-0514-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
232 Anand K, Patel T, Niravath P, Rodriguez A, Darcourt J, Belcheva A, Boone T, Ensor J, Chang J. Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy. Sci Rep 2021;11:82. [PMID: 33420229 DOI: 10.1038/s41598-020-80081-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
233 West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 2011;13:R126. [PMID: 22151962 DOI: 10.1186/bcr3072] [Cited by in Crossref: 236] [Cited by in F6Publishing: 209] [Article Influence: 23.6] [Reference Citation Analysis]
234 Bassey-Archibong BI, Rayner LG, Hercules SM, Aarts CW, Dvorkin-Gheva A, Bramson JL, Hassell JA, Daniel JM. Kaiso depletion attenuates the growth and survival of triple negative breast cancer cells. Cell Death Dis 2017;8:e2689. [PMID: 28333150 DOI: 10.1038/cddis.2017.92] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
235 Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M, Dolci MS, Azambuja ED, Hainaut P, Dell'orto P, Larsimont D, Francis PA, Crown J, Piccart-Gebhart M, Viale G, Leo AD, Olivier M. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res 2012;14:R70. [PMID: 22551440 DOI: 10.1186/bcr3179] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
236 Aranda F, Bloy N, Pesquet J, Petit B, Chaba K, Sauvat A, Kepp O, Khadra N, Enot D, Pfirschke C, Pittet M, Zitvogel L, Kroemer G, Senovilla L. Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer. Oncogene 2015;34:3053-62. [PMID: 25065595 DOI: 10.1038/onc.2014.234] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
237 Price M, Monteiro AN. Fine tuning chemotherapy to match BRCA1 status. Biochem Pharmacol 2010;80:647-53. [PMID: 20510205 DOI: 10.1016/j.bcp.2010.05.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
238 Goyal G, Fan T, Silberstein PT. Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target. Fam Cancer. 2016;15:359-366. [PMID: 26873719 DOI: 10.1007/s10689-016-9883-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
239 Birkbak NJ, Li Y, Pathania S, Greene-Colozzi A, Dreze M, Bowman-Colin C, Sztupinszki Z, Krzystanek M, Diossy M, Tung N, Ryan PD, Garber JE, Silver DP, Iglehart JD, Wang ZC, Szuts D, Szallasi Z, Richardson AL. Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers. Ann Oncol 2018;29:903-9. [PMID: 29452344 DOI: 10.1093/annonc/mdy049] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
240 Banerjee Mustafi S, Chakraborty PK, Naz S, Dwivedi SK, Street M, Basak R, Yang D, Ding K, Mukherjee P, Bhattacharya R. MDR1 mediated chemoresistance: BMI1 and TIP60 in action. Biochim Biophys Acta 2016;1859:983-93. [PMID: 27295567 DOI: 10.1016/j.bbagrm.2016.06.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
241 Zhao S, Zuo WJ, Shao ZM, Jiang YZ. Molecular subtypes and precision treatment of triple-negative breast cancer. Ann Transl Med 2020;8:499. [PMID: 32395543 DOI: 10.21037/atm.2020.03.194] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
242 Maksimenko J, Irmejs A, Nakazawa-Miklasevica M, Melbarde-Gorkusa I, Trofimovics G, Gardovskis J, Miklasevics E. Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer. Oncol Lett 2014;7:278-84. [PMID: 24348864 DOI: 10.3892/ol.2013.1684] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
243 Chalasani P, Livingston R. Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review. Oncologist 2013;18:909-16. [PMID: 23881989 DOI: 10.1634/theoncologist.2013-0039] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
244 Omarini C, Guaitoli G, Pipitone S, Moscetti L, Cortesi L, Cascinu S, Piacentini F. Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. Cancer Manag Res 2018;10:91-103. [PMID: 29391830 DOI: 10.2147/CMAR.S146658] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
245 Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010;16:53-61. [PMID: 20164691 DOI: 10.1097/PPO.0b013e3181d24ff7] [Cited by in Crossref: 184] [Cited by in F6Publishing: 105] [Article Influence: 16.7] [Reference Citation Analysis]
246 Somlo G, Lau SK, Frankel P, Hsieh HB, Liu X, Yang L, Krivacic R, Bruce RH. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat. 2011;128:155-163. [PMID: 21499685 DOI: 10.1007/s10549-011-1508-0] [Cited by in Crossref: 86] [Cited by in F6Publishing: 74] [Article Influence: 8.6] [Reference Citation Analysis]
247 Lips EH, Laddach N, Savola SP, Vollebergh MA, Oonk AM, Imholz AL, Wessels LF, Wesseling J, Nederlof PM, Rodenhuis S. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Breast Cancer Res 2011;13:R107. [PMID: 22032731 DOI: 10.1186/bcr3049] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 5.4] [Reference Citation Analysis]
248 Yu KD, Liu GY, Zhou XY, Zhou Y, Wu J, Chen CM, Shen ZZ, Shao ZM. Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant taxane-containing chemotherapy sensitivity in locally advanced breast cancer. Oncologist 2012;17:792-800. [PMID: 22561335 DOI: 10.1634/theoncologist.2011-0381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
249 Lebert JM, Lester R, Powell E, Seal M, McCarthy J. Advances in the systemic treatment of triple-negative breast cancer. Curr Oncol 2018;25:S142-50. [PMID: 29910657 DOI: 10.3747/co.25.3954] [Cited by in Crossref: 104] [Cited by in F6Publishing: 84] [Article Influence: 34.7] [Reference Citation Analysis]
250 Massink MP, Kooi IE, van Mil SE, Jordanova ES, Ameziane N, Dorsman JC, van Beek DM, van der Voorn JP, Sie D, Ylstra B, van Deurzen CH, Martens JW, Smid M, Sieuwerts AM, de Weerd V, Foekens JA, van den Ouweland AM, van Dyk E, Nederlof PM, Waisfisz Q, Meijers-Heijboer H. Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes. Mol Oncol 2015;9:877-88. [PMID: 25616998 DOI: 10.1016/j.molonc.2014.12.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
251 Shuen AY, Foulkes WD. Inherited mutations in breast cancer genes--risk and response. J Mammary Gland Biol Neoplasia. 2011;16:3-15. [PMID: 21461995 DOI: 10.1007/s10911-011-9213-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
252 Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer. 2015;121:8-16. [PMID: 25043972 DOI: 10.1002/cncr.28914] [Cited by in Crossref: 169] [Cited by in F6Publishing: 166] [Article Influence: 24.1] [Reference Citation Analysis]
253 Park JH, Ahn JH, Kim SB. How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. ESMO Open 2018;3:e000357. [PMID: 29765774 DOI: 10.1136/esmoopen-2018-000357] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 17.7] [Reference Citation Analysis]
254 Guo L, Lee YT, Zhou Y, Huang Y. Targeting epigenetic regulatory machinery to overcome cancer therapy resistance. Semin Cancer Biol 2021:S1044-579X(20)30282-0. [PMID: 33421619 DOI: 10.1016/j.semcancer.2020.12.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
255 Rojas-Jiménez E, Mejía-Gómez JC, Díaz-Velásquez C, Quezada-Urban R, Martínez Gregorio H, Vallejo-Lecuona F, de la Cruz-Montoya A, Porras Reyes FI, Pérez-Sánchez VM, Maldonado-Martínez HA, Robles-Estrada M, Bargalló-Rocha E, Cabrera-Galeana P, Ramos-Ramírez M, Chirino YI, Alonso Herrera L, Terrazas LI, Oliver J, Frecha C, Perdomo S, Vaca-Paniagua F. Comprehensive Genomic Profile of Heterogeneous Long Follow-Up Triple-Negative Breast Cancer and Its Clinical Characteristics Shows DNA Repair Deficiency Has Better Prognostic. Genes (Basel) 2020;11:E1367. [PMID: 33227964 DOI: 10.3390/genes11111367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
256 Ayala-Orozco C, Urban C, Bishnoi S, Urban A, Charron H, Mitchell T, Shea M, Nanda S, Schiff R, Halas N, Joshi A. Sub-100nm gold nanomatryoshkas improve photo-thermal therapy efficacy in large and highly aggressive triple negative breast tumors. J Control Release 2014;191:90-7. [PMID: 25051221 DOI: 10.1016/j.jconrel.2014.07.038] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 8.4] [Reference Citation Analysis]
257 Brunetto AT, Sarker D, Papadatos-Pastos D, Fehrmann R, Kaye SB, Johnston S, Allen M, De Bono JS, Swanton C. A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit. Br J Cancer 2010;103:607-12. [PMID: 20664586 DOI: 10.1038/sj.bjc.6605812] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
258 Español A, Salem A, Sanchez Y, Sales ME. Breast cancer: Muscarinic receptors as new targets for tumor therapy. World J Clin Oncol 2021;12:404-28. [PMID: 34189066 DOI: 10.5306/wjco.v12.i6.404] [Reference Citation Analysis]
259 Brown KK, Spinelli JB, Asara JM, Toker A. Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer. Cancer Discov 2017;7:391-9. [PMID: 28255083 DOI: 10.1158/2159-8290.CD-16-0611] [Cited by in Crossref: 83] [Cited by in F6Publishing: 52] [Article Influence: 20.8] [Reference Citation Analysis]
260 Kedzierawski P, Macek P, Ciepiela I, Kowalik A, Gozdz S. Evaluation of Complete Pathological Regression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients with BRCA1 Founder Mutation Aided Bayesian A/B Testing Approach. Diagnostics (Basel) 2021;11:1144. [PMID: 34201809 DOI: 10.3390/diagnostics11071144] [Reference Citation Analysis]
261 Han Y, Wang J, Xu B. Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer. J Cancer 2021;12:936-45. [PMID: 33403050 DOI: 10.7150/jca.52439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
262 Nogales V, Reinhold WC, Varma S, Martinez-Cardus A, Moutinho C, Moran S, Heyn H, Sebio A, Barnadas A, Pommier Y, Esteller M. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. Oncotarget 2016;7:3084-97. [PMID: 26625211 DOI: 10.18632/oncotarget.6413] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 15.4] [Reference Citation Analysis]
263 Hambrecht A, Jandial R, Neman J. Emerging role of brain metastases in the prognosis of breast cancer patients. Breast Cancer (Dove Med Press) 2011;3:79-91. [PMID: 24367178 DOI: 10.2147/BCTT.S19967] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
264 Stefansson OA, Villanueva A, Vidal A, Martí L, Esteller M. BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics. 2012;7:1225-1229. [PMID: 23069641 DOI: 10.4161/epi.22561] [Cited by in Crossref: 88] [Cited by in F6Publishing: 66] [Article Influence: 9.8] [Reference Citation Analysis]
265 Annunziata CM, O'Shaughnessy J. Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin Cancer Res. 2010;16:4517-4526. [PMID: 20823142 DOI: 10.1158/1078-0432.ccr-10-0526] [Cited by in Crossref: 69] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
266 Meng XL, Su D, Wang L, Gao Y, Hu YJ, Yang HJ, Xie SN. Low expression of stathmin in tumor predicts high response to neoadjuvant chemotherapy with docetaxel-containing regimens in locally advanced breast cancer. Genet Test Mol Biomarkers 2012;16:689-94. [PMID: 22480216 DOI: 10.1089/gtmb.2011.0298] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
267 Saha P, Nanda R. Concepts and targets in triple-negative breast cancer: recent results and clinical implications. Ther Adv Med Oncol 2016;8:351-9. [PMID: 27583027 DOI: 10.1177/1758834016657071] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
268 Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA, Rugo HS. The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis 2012;29:807-19. [PMID: 22692561 DOI: 10.1007/s10585-012-9496-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
269 Cowherd S, Miller LD, Melin SA, Akman S, Isom S, Cole J, Pullikuth A, Lawrence JA. A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer. Cancer Biol Ther 2015;16:678-83. [PMID: 25928118 DOI: 10.1080/15384047.2015.1026481] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
270 Nicolas E, Bertucci F, Sabatier R, Gonçalves A. Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives? Cancers (Basel) 2018;10:E506. [PMID: 30544963 DOI: 10.3390/cancers10120506] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
271 Heijink AM, Everts M, Honeywell ME, Richards R, Kok YP, de Vries EGE, Lee MJ, van Vugt MATM. Modeling of Cisplatin-Induced Signaling Dynamics in Triple-Negative Breast Cancer Cells Reveals Mediators of Sensitivity. Cell Rep 2019;28:2345-2357.e5. [PMID: 31461651 DOI: 10.1016/j.celrep.2019.07.070] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
272 Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol 2020;38:388-94. [PMID: 31461380 DOI: 10.1200/JCO.19.01304] [Cited by in Crossref: 48] [Cited by in F6Publishing: 26] [Article Influence: 24.0] [Reference Citation Analysis]
273 Hahm ER, Lee J, Abella T, Singh SV. Withaferin A inhibits expression of ataxia telangiectasia and Rad3-related kinase and enhances sensitivity of human breast cancer cells to cisplatin. Mol Carcinog 2019;58:2139-48. [PMID: 31441116 DOI: 10.1002/mc.23104] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
274 La Belle A, Khatib J, Schiemann WP, Vinayak S. Role of Platinum in Early-Stage Triple-Negative Breast Cancer. Curr Treat Options Oncol 2017;18:68. [PMID: 29110096 DOI: 10.1007/s11864-017-0506-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
275 Meng X, Chen H, Wang G, Yu Y, Xie K. Hydrogen-rich saline attenuates chemotherapy-induced ovarian injury via regulation of oxidative stress. Exp Ther Med 2015;10:2277-82. [PMID: 26668628 DOI: 10.3892/etm.2015.2787] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
276 Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7:683-692. [PMID: 20877296 DOI: 10.1038/nrclinonc.2010.154] [Cited by in Crossref: 495] [Cited by in F6Publishing: 463] [Article Influence: 45.0] [Reference Citation Analysis]
277 Cosentino G, Romero-Cordoba S, Plantamura I, Cataldo A, Iorio MV. miR-9-Mediated Inhibition of EFEMP1 Contributes to the Acquisition of Pro-Tumoral Properties in Normal Fibroblasts. Cells 2020;9:E2143. [PMID: 32972039 DOI: 10.3390/cells9092143] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
278 Marquard AM, Eklund AC, Joshi T, Krzystanek M, Favero F, Wang ZC, Richardson AL, Silver DP, Szallasi Z, Birkbak NJ. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res 2015;3:9. [PMID: 26015868 DOI: 10.1186/s40364-015-0033-4] [Cited by in Crossref: 100] [Cited by in F6Publishing: 81] [Article Influence: 16.7] [Reference Citation Analysis]
279 Sheppard VB, Cavalli LR, Dash C, Kanaan YM, Dilawari AA, Horton S, Makambi KH. Correlates of Triple Negative Breast Cancer and Chemotherapy Patterns in Black and White Women With Breast Cancer. Clin Breast Cancer 2017;17:232-8. [PMID: 28189497 DOI: 10.1016/j.clbc.2016.12.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
280 Di Cosimo S, La Verde N, Moretti A, Cazzaniga ME, Generali D, Bianchi GV, Mariani L, Torri V, Crippa F, Paolini B, Scaperrotta G, De Santis MC, Di Nicola M, Apolone G, Gulino A, Tripodo C, Colombo MP, Folli S, de Braud F. Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study. PLoS One 2019;14:e0220644. [PMID: 31390375 DOI: 10.1371/journal.pone.0220644] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
281 Beck AH, Knoblauch NW, Hefti MM, Kaplan J, Schnitt SJ, Culhane AC, Schroeder MS, Risch T, Quackenbush J, Haibe-Kains B. Significance analysis of prognostic signatures. PLoS Comput Biol 2013;9:e1002875. [PMID: 23365551 DOI: 10.1371/journal.pcbi.1002875] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
282 de Kruijff IE, Sieuwerts AM, Beije N, Prager-van der Smissen WJC, Angus L, Beaufort CM, Van MN, Oomen-de Hoop E, Jager A, Hamberg P, de Jongh FE, Kraan J, Martens JWM, Sleijfer S. Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients. Front Oncol 2021;11:697572. [PMID: 34249756 DOI: 10.3389/fonc.2021.697572] [Reference Citation Analysis]
283 Peddi PF, Ellis MJ, Ma C. Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer. 2012;2012:217185. [PMID: 22295242 DOI: 10.1155/2012/217185] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 5.8] [Reference Citation Analysis]
284 Nasr KE, Osman MA, Elkady MS, Ellithy MA. Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study. Ann Transl Med. 2015;3:284. [PMID: 26697444 DOI: 10.3978/j.issn.2305-5839.2015.11.14] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
285 Setyawati Y, Rahmawati Y, Widodo I, Ghozali A, Purnomosari D. The Association between Molecular Subtypes of Breast Cancer with Histological Grade and Lymph Node Metastases in Indonesian Woman. Asian Pac J Cancer Prev 2018;19:1263-8. [PMID: 29801411 DOI: 10.22034/APJCP.2018.19.5.1263] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
286 Li S, Li Q, Lü J, Zhao Q, Li D, Shen L, Wang Z, Liu J, Xie D, Cho WC, Xu S, Yu Z. Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells. Front Genet 2019;10:1278. [PMID: 32010177 DOI: 10.3389/fgene.2019.01278] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
287 Ruiz de Garibay G, Mateo F, Stradella A, Valdés-Mas R, Palomero L, Serra-Musach J, Puente DA, Díaz-Navarro A, Vargas-Parra G, Tornero E, Morilla I, Farré L, Martinez-Iniesta M, Herranz C, McCormack E, Vidal A, Petit A, Soler T, Lázaro C, Puente XS, Villanueva A, Pujana MA. Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance. Dis Model Mech 2018;11:dmm032292. [PMID: 29666142 DOI: 10.1242/dmm.032292] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
288 Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, Carey LA. Poly(ADP-Ribose) polymerase inhibition: “targeted” therapy for triple-negative breast cancer. Clin Cancer Res. 2010;16:4702-4710. [PMID: 20858840 DOI: 10.1158/1078-0432.ccr-10-0939] [Cited by in Crossref: 105] [Cited by in F6Publishing: 67] [Article Influence: 9.5] [Reference Citation Analysis]
289 Lazaro T, Brastianos PK. Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. CNS Oncol 2017;6:139-51. [PMID: 28425754 DOI: 10.2217/cns-2016-0038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
290 Banerjee I, Malladi S, Lee D, Depeursinge A, Telli M, Lipson J, Golden D, Rubin DL. Assessing treatment response in triple-negative breast cancer from quantitative image analysis in perfusion magnetic resonance imaging. J Med Imaging (Bellingham) 2018;5:011008. [PMID: 29134191 DOI: 10.1117/1.JMI.5.1.011008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
291 Caramelo O, Silva C, Caramelo F, Frutuoso C, Almeida-Santos T. The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis. Hered Cancer Clin Pract 2019;17:11. [PMID: 30962858 DOI: 10.1186/s13053-019-0111-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
292 Mylavarapu S, Das A, Roy M. Role of BRCA Mutations in the Modulation of Response to Platinum Therapy. Front Oncol 2018;8:16. [PMID: 29459887 DOI: 10.3389/fonc.2018.00016] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 14.0] [Reference Citation Analysis]
293 Chen Z, Ai L, Mboge MY, McKenna R, Frost CJ, Heldermon CD, Frost SC. UFH-001 cells: A novel triple negative, CAIX-positive, human breast cancer model system. Cancer Biol Ther 2018;19:598-608. [PMID: 29561695 DOI: 10.1080/15384047.2018.1449612] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
294 Woodman JL, Suh MS, Zhang J, Kondaveeti Y, Burgess DJ, White BA, Prestwich GD, Kuhn LT. Carboxymethyl Hyaluronan-Stabilized Nanoparticles for Anticancer Drug Delivery. Int J Cell Biol 2015;2015:249573. [PMID: 26448751 DOI: 10.1155/2015/249573] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
295 Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, Haffty BG, Tommiska J, Blomqvist C, Drapkin R, Adams DJ, Nevanlinna H, Bartek J, Tarsounas M, Ganesan S, Jonkers J. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010;17:688-95. [PMID: 20453858 DOI: 10.1038/nsmb.1831] [Cited by in Crossref: 635] [Cited by in F6Publishing: 567] [Article Influence: 57.7] [Reference Citation Analysis]
296 Galassi R, Luciani L, Gambini V, Vincenzetti S, Lupidi G, Amici A, Marchini C, Wang J, Pucciarelli S. Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells. Front Chem 2020;8:602845. [PMID: 33490036 DOI: 10.3389/fchem.2020.602845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
297 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
298 Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin Cancer Res. 2014;20:782-790. [PMID: 24536073 DOI: 10.1158/1078-0432.ccr-13-0583] [Cited by in Crossref: 186] [Cited by in F6Publishing: 116] [Article Influence: 26.6] [Reference Citation Analysis]
299 Zeng Y, Wang G, Zhou CF, Zhang HB, Sun H, Zhang W, Zhou HH, Liu R, Zhu YS. LncRNA Profile Study Reveals a Three-LncRNA Signature Associated With the Pathological Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer. Front Pharmacol 2019;10:574. [PMID: 31191314 DOI: 10.3389/fphar.2019.00574] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
300 Lee MT, Ho SM, Tarapore P, Chung I, Leung YK. Estrogen receptor β isoform 5 confers sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis through interaction with Bcl2L12. Neoplasia 2013;15:1262-71. [PMID: 24339738 DOI: 10.1593/neo.131184] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
301 Lohinai Z, Megyesfalvi Z, Dome B, Weiss GJ. Next-Generation Sequencing May Discriminate Extreme Long-term versus Short-term Survival in Patients with Metastatic Small Cell Lung Cancer (SCLC). Transl Oncol 2019;12:1539-48. [PMID: 31476386 DOI: 10.1016/j.tranon.2019.08.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
302 Luo Y, Zhang W, Xu L, Chen Y, Xu Y, Yuan L. Long Non-Coding RNA PVT1 Regulates the Resistance of the Breast Cancer Cell Line MDA-MB-231 to Doxorubicin via Nrf2. Technol Cancer Res Treat 2020;19:1533033820980763. [PMID: 33327894 DOI: 10.1177/1533033820980763] [Reference Citation Analysis]
303 Abdel-Fatah TM, Arora A, Moseley PM, Perry C, Rakha EA, Green AR, Chan SY, Ellis IO, Madhusudan S. DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers. Oncotarget 2015;6:21964-78. [PMID: 26267318 DOI: 10.18632/oncotarget.4157] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
304 Campos-Parra AD, López-Urrutia E, Orozco Moreno LT, López-Camarillo C, Meza-Menchaca T, Figueroa González G, Bustamante Montes LP, Pérez-Plasencia C. Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer. Int J Mol Sci 2018;19:E2711. [PMID: 30208633 DOI: 10.3390/ijms19092711] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
305 Smith KL, Isaacs C. BRCA mutation testing in determining breast cancer therapy. Cancer J 2011;17:492-9. [PMID: 22157293 DOI: 10.1097/PPO.0b013e318238f579] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
306 Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, Ruiz-Borrego M, Munarriz B, López JA, Adamo B, Cheang MC, Li Y, Hu Z, Gulley ML, Vidal MJ, Pitcher BN, Liu MC, Citron ML, Ellis MJ, Mardis E, Vickery T, Hudis CA, Winer EP, Carey LA, Caballero R, Carrasco E, Martín M, Perou CM, Alba E. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br J Cancer 2014;111:1532-41. [PMID: 25101563 DOI: 10.1038/bjc.2014.444] [Cited by in Crossref: 67] [Cited by in F6Publishing: 53] [Article Influence: 9.6] [Reference Citation Analysis]
307 Imyanitov EN, Moiseyenko VM. Drug therapy for hereditary cancers. Hered Cancer Clin Pract 2011;9:5. [PMID: 21819606 DOI: 10.1186/1897-4287-9-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
308 Vetter M, Fokas S, Biskup E, Schmid T, Schwab F, Schoetzau A, Güth U, Rochlitz C, Zanetti-Dällenbach R. Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience. Oncotarget 2017;8:75617-26. [PMID: 29088896 DOI: 10.18632/oncotarget.18118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
309 Kanapathy Pillai SK, Tay A, Nair S, Leong CO. Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women. BMC Clin Pathol 2012;12:18. [PMID: 23009686 DOI: 10.1186/1472-6890-12-18] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
310 Wang R, Wang S, Chan S, Wang Y, Zhang Y, Zuo Z, Chi-Fung Chan G, Li H, Sun H. Bismuth Porphyrin Antagonizes Cisplatin-Induced Nephrotoxicity via Unexpected Metallothionein-Independent Mechanisms. iScience 2020;23:101054. [PMID: 32353763 DOI: 10.1016/j.isci.2020.101054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
311 Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J, Orr N, Parton M, Smith IE, Reis-Filho JS, Dowsett M, Ashworth A, Turner NC. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010;16:6159-68. [PMID: 20802015 DOI: 10.1158/1078-0432.CCR-10-1027] [Cited by in Crossref: 210] [Cited by in F6Publishing: 110] [Article Influence: 19.1] [Reference Citation Analysis]
312 Lee JM, Hays JL, Chiou VL, Annunziata CM, Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, Kohn EC. Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. Oncotarget 2017;8:79175-87. [PMID: 29108297 DOI: 10.18632/oncotarget.16577] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
313 Schätzle LK, Hadizadeh Esfahani A, Schuppert A. Methodological challenges in translational drug response modeling in cancer: A systematic analysis with FORESEE. PLoS Comput Biol 2020;16:e1007803. [PMID: 32310964 DOI: 10.1371/journal.pcbi.1007803] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
314 Sharma P, López-Tarruella S, García-Saenz JA, Ward C, Connor CS, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortes J, Fuentes Rivera H, Bretel Morales D, Márquez-Rodas I, Perou CM, Wagner JL, Mammen JM, McGinness MK, Klemp JR, Amin AL, Fabian CJ, Heldstab J, Godwin AK, Jensen RA, Kimler BF, Khan QJ, Martin M. Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. Clin Cancer Res 2017;23:649-57. [PMID: 27301700 DOI: 10.1158/1078-0432.CCR-16-0162] [Cited by in Crossref: 59] [Cited by in F6Publishing: 27] [Article Influence: 11.8] [Reference Citation Analysis]
315 Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Palmer HG, Dawood S, Rodón J, Ramon y Cajal S, Del Campo JM, Felip E, Tabernero J, Cortés J. Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. Sci Rep 2013;3:3544. [PMID: 24384914 DOI: 10.1038/srep03544] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
316 Rodenhiser DI, Andrews JD, Vandenberg TA, Chambers AF. Gene signatures of breast cancer progression and metastasis. Breast Cancer Res. 2011;13:201. [PMID: 21345283 DOI: 10.1186/bcr2791] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
317 John T, Starmans MH, Chen YT, Russell PA, Barnett SA, White SC, Mitchell PL, Walkiewicz M, Azad A, Lambin P, Tsao MS, Deb S, Altorki N, Wright G, Knight S, Boutros PC, Cebon JS. The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer. PLoS One 2013;8:e67876. [PMID: 23935846 DOI: 10.1371/journal.pone.0067876] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
318 Shao F, Sun H, Deng CX. Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype. Oncotarget. 2017;8:73329-73344. [PMID: 29069872 DOI: 10.18632/oncotarget.20274] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 9.3] [Reference Citation Analysis]
319 Iyevleva AG, Imyanitov EN. Cytotoxic and targeted therapy for hereditary cancers. Hered Cancer Clin Pract. 2016;14:17. [PMID: 27555886 DOI: 10.1186/s13053-016-0057-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
320 Arranz EE, Vara JÁ, Gámez-Pozo A, Zamora P. Gene signatures in breast cancer: current and future uses. Transl Oncol 2012;5:398-403. [PMID: 23323153 DOI: 10.1593/tlo.12244] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
321 Yam C, Mani SA, Moulder SL. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field. Oncologist 2017;22:1086-93. [PMID: 28559413 DOI: 10.1634/theoncologist.2017-0095] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 10.8] [Reference Citation Analysis]
322 Satyananda V, Oshi M, Endo I, Takabe K. High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer. Ann Surg Oncol 2021. [PMID: 33966140 DOI: 10.1245/s10434-021-10063-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
323 Mancini P, Angeloni A, Risi E, Orsi E, Mezi S. Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers (Basel) 2014;6:2187-223. [PMID: 25347122 DOI: 10.3390/cancers6042187] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
324 EL Baiomy MA, El Kashef WF. ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy. Asian Pac J Cancer Prev 2017;18:507-13. [PMID: 28345838 DOI: 10.22034/APJCP.2017.18.2.507] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
325 Tan TZ, Miow QH, Miki Y, Noda T, Mori S, Huang RY, Thiery JP. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med 2014;6:1279-93. [PMID: 25214461 DOI: 10.15252/emmm.201404208] [Cited by in Crossref: 351] [Cited by in F6Publishing: 294] [Article Influence: 58.5] [Reference Citation Analysis]
326 Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016;13:674-90. [PMID: 27184417 DOI: 10.1038/nrclinonc.2016.66] [Cited by in Crossref: 903] [Cited by in F6Publishing: 805] [Article Influence: 180.6] [Reference Citation Analysis]
327 Seshie B, Adu-Aryee NA, Dedey F, Calys-Tagoe B, Clegg-Lamptey JN. A retrospective analysis of breast cancer subtype based on ER/PR and HER2 status in Ghanaian patients at the Korle Bu Teaching Hospital, Ghana. BMC Clin Pathol 2015;15:14. [PMID: 26161039 DOI: 10.1186/s12907-015-0014-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
328 Schoonen PM, Talens F, Stok C, Gogola E, Heijink AM, Bouwman P, Foijer F, Tarsounas M, Blatter S, Jonkers J, Rottenberg S, van Vugt MATM. Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells. Nat Commun. 2017;8:15981. [PMID: 28714471 DOI: 10.1038/ncomms15981] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 13.5] [Reference Citation Analysis]
329 Tung N, Arun B, Hacker MR, Hofstatter E, Toppmeyer DL, Isakoff SJ, Borges V, Legare RD, Isaacs C, Wolff AC, Marcom PK, Mayer EL, Lange PB, Goss AJ, Jenkins C, Krop IE, Winer EP, Schnitt SJ, Garber JE. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). J Clin Oncol 2020;38:1539-48. [PMID: 32097092 DOI: 10.1200/JCO.19.03292] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 28.0] [Reference Citation Analysis]
330 Ribeiro J, Sousa B, Cardoso F. Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment. EJC Suppl 2013;11:3-22. [PMID: 26217109 DOI: 10.1016/j.ejcsup.2013.07.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
331 Geck RC, Foley JR, Murray Stewart T, Asara JM, Casero RA Jr, Toker A. Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy. J Biol Chem 2020;295:6263-77. [PMID: 32139506 DOI: 10.1074/jbc.RA119.012376] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
332 Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, DeFazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD, Matulonis UA; Australian Ovarian Cancer Study Group. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res 2012;18:5806-15. [PMID: 22912389 DOI: 10.1158/1078-0432.CCR-12-0857] [Cited by in Crossref: 108] [Cited by in F6Publishing: 64] [Article Influence: 12.0] [Reference Citation Analysis]
333 Hill SJ, Rolland T, Adelmant G, Xia X, Owen MS, Dricot A, Zack TI, Sahni N, Jacob Y, Hao T, McKinney KM, Clark AP, Reyon D, Tsai SQ, Joung JK, Beroukhim R, Marto JA, Vidal M, Gaudet S, Hill DE, Livingston DM. Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage. Genes Dev 2014;28:1957-75. [PMID: 25184681 DOI: 10.1101/gad.241620.114] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 8.9] [Reference Citation Analysis]